All In Biotech

NDA 207962 · Scilex Pharms

Ztlido

Lidocaine · Topical · Amide Local Anesthetic; Antiarrhythmic

Last checked: Nov 20, 2026Latest source record: Apr 8, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Feb 28, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

2,569

373 Phase 3, 196 recruiting

FAERS reports

49,881

36,261 serious, 5,056 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 1, 2024.

ZTLIDO is indicated for relief of pain associated with post-herpetic neuralgia (PHN) in adults. ZTLIDO contains lidocaine, an amide local anesthetic, and is indicated for relief of pain associated with post-herpetic neuralgia (PHN) in adults ( 1 ).

Mechanism: Lidocaine is an amide local anesthetic. Lidocaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 8, 2021 Supplement 5 · Efficacy LetterLabel
  • Feb 28, 2018 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • ZTLIDO · LIDOCAINE 1.8% · PATCH, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lidocaine" as an intervention, any sponsor and status, largest first.

All 2,569 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,715
  • pain3,226
  • fatigue3,117
  • nausea3,103
  • headache2,866
  • off label use2,726
  • dyspnoea2,224
  • pneumonia2,056
  • diarrhoea2,017
  • sinusitis1,952
  • vomiting1,889
  • product dose omission issue1,772

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004281
2005257
2006318
2007314
2008376
2009451
2010531
20111,089
20121,215
2013757
20141,133
20151,871
20163,208
20172,539
20183,298
20194,174
20205,431
20213,793
20223,546
20233,900
20244,006
20254,135
20263,254

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ztlido (Lidocaine)

2024 spending

$50.5M

Beneficiaries

21,360

81,208 claims

Per beneficiary

$2,362

$11.64 per unit

View as table
YearSpending
2020$20,170,644
2021$25,768,122
2022$35,554,588
2023$50,681,852
2024$50,458,699

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,282 on PubMed

Sponsor: Scilex Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.